Increased androgen receptor transcription: A cause of castration-resistant prostate cancer and a possible therapeutic target

Journal of Molecular Endocrinology

Volumn 47, Issue 1, 2011, Pages

  Shiota, Masaki ^a   Yokomizo, Akira ^a   Naito, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; ALITRETINOIN; ANDROGEN RECEPTOR; AZ 10397767; BAICALIN; BUTYRIC ACID; CALCIMYCIN; CELECOXIB; CLIOQUINOL; CP 248; CP 461; DEPSIPEPTIDE; DIBENZOYLMETHANE DERIVATIVE; DOXORUBICIN; ETOPOSIDE; FULVESTRANT; GENISTEIN; HYDROXYFLUTAMIDE; METRIBOLONE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARTHENOLIDE; QUERCETIN; RESVERATROL; SELENITE; SELENIUM; SULINDAC SULFIDE; SULINDAC SULFONE; THAPSIGARGIN; THYMOQUINONE; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

APOPTOSIS; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COMPETITIVE INHIBITION; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS; NONHUMAN; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATECTOMY; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION; UPREGULATION; VITAMIN SUPPLEMENTATION;

ANDROGEN RECEPTOR ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TREATMENT FAILURE;

EID: 79960979238     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-11-0018     Document Type: Review

References (187)

1. Abbas A & Gupta S 2008 The role of histone deacetylases in prostate cancer. Epigenetics 3 300-309. (doi:10.4161/epi.3.6.7273)
2. Adam RM, Kim J, Lin J, Orsola A, Zhuang L, Rice DC & Freeman MR 2002 Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function. Endocrinology 143 4599-4608. (doi:10.1210/en.2002-220561)
3. Adhikary S & Eilers M 2005 Transcriptional regulation and transformation by Myc proteins. Nature Reviews. Molecular Cell Biology 6 635-645. (doi:10.1038/nrm1703)
4. Alimirah F, Panchanathan R, Chen J, Zhang X, Ho SM & Choubey D 2007 Expression of androgen receptor is negatively regulated by p53. Neoplasia 9 1152-1159. (doi:10.1593/neo.07769)
5. Ameyar M, Wisniewska M & Weitzman JB 2003 A role for AP-1 in apoptosis: the case for and against. Biochimie 85 747-752. (doi:10.1016/j.biochi.2003.09.006)
6. Barr SM & Johnson EM 2001 Ras-induced colony formation and anchorage-independent growth inhibited by elevated expression of Pura in NIH3T3 cells. Journal of Cellular Biochemistry 81 621-638. (doi:10.1002/jcb.1099)
7. Bauer JJ, Sesterhenn IA, Mostofi KF, McLeod DG, Srivastava S & Moul JW. 1995 p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clinical Cancer Research 1 1295-1300.
8. Bergemann AD & Johnson EM 1992 The HeLa Pur factor binds singlestranded DNA at a specific element conserved in gene flanking regions and origins of DNA replication. Molecular and Cellular Biology 12 1257-1265.
9. Bergemann AD, Ma ZW & Johnson EM 1992 Sequence of cDNA comprising the human pur gene and sequence-specific singlestranded- DNA-binding properties of the encoded protein. Molecular and Cellular Biology 12 5673-5682.
10. Bhattacharyya RS, Krishnan AV, Swami S & Feldman D 2006 Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Molecular Cancer Therapeutics 5 1539-1549. (doi:10.1158/1535-7163.MCT-06-0065)
11. Bhattacharyya RS, Husbeck B, Feldman D & Knox SJ 2008 Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer. International Journal of Radiation Oncology, Biology, Physics 72 935-940. (doi:10.1016/j.ijrobp.2008.07.005)
12. Black AR, Black JD & Azizkhan-Clifford J 2001 Sp1 and Krüppel-like factor family of transcription factors in cell growth regulation and cancer. Journal of Cellular Physiology 188 143-160. (doi:10.1002/jcp.1111)
13. Boxer LM & Dang CV 2001 Translocations involving c-myc and c-myc function. Oncogene 20 5595-5610. (doi:10.1038/sj.onc.1204595)
14. Bradley D, Rathkopf D, Dunn R, Stadler WM, Liu G, Smith DC, Pili R, Zwiebel J, Scher H & Hussain M 2009 Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 115 5541-5549. (doi:10.1002/cncr.24597)
15. Brasier AR 2006 The NF-kB regulatory network. Cardiovascular Toxicology 6 111-130. (doi:10.1385/CT:6:2:111)
16. Brinkmann AO, Faber PW, van Rooij HC, Kuiper GG, Ris C, Klaassen P, van der Korput JA, Voorhorst MM, van Laar JH, Mulder E et al. 1989 The human androgen receptor: domain structure, genomic organization and regulation of expression. Journal of Steroid Biochemistry 34 307-310. (doi:10.1016/0022-4731(89)90098-8)
17. Bubulya A, Zhou XF, Shen XQ, Fisher CJ & Shemshedini L 2000 c-Jun targets amino terminus of androgen receptor in regulating androgen-responsive transcription. Endocrine 13 55-62. (doi:10.1385/ENDO:13:1:55)
18. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA & Richon VM 2000 Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Research 60 5165-5170.
19. Chang CF, Gallia GL, Muralidharan V, Chen NN, Zoltick P, Johnson E & Khalili K 1996 Evidence that replication of human neurotropic JC virus DNA in glial cells is regulated by the sequence-specific singlestranded DNA-binding protein Pura. Journal of Virology 70 4150-4156.
20. Chen CD & Sawyers CL 2002 NF-kB activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Molecular and Cellular Biology 22 2862-2870. (doi:10.1128/MCB.22.8.2862-2870.2002)
21. Chen S, Ruan Q, Bedner E, Deptala A, Wang X, Hsieh TC, Traganos F & Darzynkiewicz Z 2001 Effects of the flavonoid baicalin and its metabolite baicalein on androgen receptor expression, cell cycle progression and apoptosis of prostate cancer cell lines. Cell Proliferation 34 293-304. (doi:10.1046/j.0960-7722.2001.00213.x)
22. Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D & Rabbani SA 2004a Up-regulation of Wnt-1 and b-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 101 1345-1356. (doi:10.1002/cncr.20518)
23. Chen SY, Cai C, Fisher CJ, Zheng Z, Omwancha J, Hsieh CL & Shemshedini L 2006 c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation. Oncogene 25 7212-7223. (doi:10.1038/sj.onc.1209705)
24. Chen D, Cui QC, Yang H, Barrea RA, Sarkar FH, Sheng S, Yan B, Reddy GP & Dou QP 2007 Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer Research 67 1636-1644. (doi:10.1158/0008-5472.CAN-06-3546)
25. Chen H, Liu W, Roberts W, Hooker S, Fedor H, DeMarzo A, Isaacs W & Kittles RA 2010 8q24 allelic imbalance and MYC gene copy number in primary prostate cancer. Prostate Cancer and Prostatic Diseases 13 238-243. (doi:10.1038/pcan.2010.20)
26. Chintharlapalli S, Papineni S & Safe S 2007 1,1-bis(30-indolyl)-1-(p-substitutedphenyl)methanes inhibit growth, induce apoptosis, and decrease the androgen receptor in LNCaP prostate cancer cells through peroxisome proliferator-activated receptor gammaindependent pathways. Molecular Pharmacology 71 558-569. (doi:10.1124/mol.106.028696)
27. Chiu FL & Lin JK 2008 Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts. Prostate 68 61-71. (doi:10.1002/pros.20690)
28. Chun JY, Nadiminty N, Lee SO, Onate SA, Lou W & Gao AC 2006 Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancer. Molecular Cancer Therapeutics 5 913-918. (doi:10.1158/1535-7163.MCT-05-0389)
29. Darbinian N, Gallia GL, Kundu M, Shcherbik N, Tretiakova A, Giordano A & Khalili K 1999 Association of Pura and E2F-1 suppresses transcriptional activity of E2F-1. Oncogene 18 6398-6402. (doi:10.1038/sj.onc.1203011)
30. Darbinian N, Gallia GL, King J, Del Valle L, Johnson EM & Khalili K 2001 Growth inhibition of glioblastoma cells by human Pura. Journal of Cellular Physiology 189 334-340. (doi:10.1002/jcp.10029)
31. Davis JN, Wojno KJ, Daignault S, Hofer MD, Kuefer R, Rubin MA & Day M 2006 Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Research 66 11897-11906. (doi:10.1158/0008-5472.CAN-06-2497)
32. Debes JD & Tindall DJ 2004 Mechanisms of androgen-refractory prostate cancer. New England Journal of Medicine 351 1488-1490. (doi:10.1056/NEJMp048178)
33. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL & Tindall DJ 2008 Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Research 68 5469-5477. (doi:10.1158/0008-5472.CAN-08-0594)
34. Deng X, Liu H, Huang J, Cheng L, Keller ET, Parsons SJ & Hu CD 2008 Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Research 68 9663-9670. (doi:10.1158/0008-5472.CAN-08-2229)
35. Ding Y, Yuan HQ, Kong F, Hu XY, Ren K, Cai J, Wang XL & Young CY 2007 Ectopic expression of neurotrophic peptide derived from saposin C increases proliferation and upregulates androgen receptor expression and transcriptional activity in human prostate cancer cells. Asian Journal of Andrology 9 601-609. (doi:10.1111/j.1745-7262.2007.00328.x)
36. Dong Y, Zhang H, Hawthorn L, Ganther HE & Ip C 2003 Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Research 63 52-59.
37. van Doorn R, Dijkman R, Vermeer MH, Out-Luiting JJ, van der Raaij-Helmer EM, Willemze R & Tensen CP 2004 Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary syndrome identified by gene expression analysis. Cancer Research 64 5578-5586. (doi:10.1158/0008-5472.CAN-04-1253)
38. Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, Marshall JR, Clark LC & Nutritional Prevention of Cancer Study Group 2003 Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International 91 608-612. (doi:10.1046/j.1464-410X.2003.04167.x)
39. Durham SK, Suwanichkul A, Scheimann AO, Yee D, Jackson JG, Barr FG & Powell DR 1999 FKHRbinds the insulin response element in the insulin-like growth factor binding protein-1 promoter. Endocrinology 140 3140-3146. (doi:10.1210/en.140.7.3140)
40. Edwards J, Krishna NS, Mukherjee R & Bartlett JM 2004 The role of c-Jun and c-Fos expression in androgen-independent prostate cancer. Journal of Pathology 204 153-158. (doi:10.1002/path.1605)
41. Ekoff M, Kaufmann T, Engström M, Motoyama N, Villunger A, Jönsson JI, Strasser A & Nilsson G 2007 The BH3-only protein Puma plays an essential role in cytokine deprivation induced apoptosis of mast cells. Blood 110 3209-3217. (doi:10.1182/blood-2007-02-073957)
42. Emami KH, Brown LG, Pitts TE, Sun X, Vessella RL & Corey E 2009 Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells. Prostate 69 1481-1492. (doi:10.1002/pros.20998)
43. Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME & Nelson CC 2004 Dysregulation of sterol response elementbinding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Research 64 2212-2221. (doi:10.1158/0008-5472.CAN-2148-2)
44. Faber PW, van Rooij HC, van der Korput HA, Baarends WM, Brinkmann AO, Grootegoed JA & Trapman J 1991 Characterization of the human androgen receptor transcription unit. Journal of Biological Chemistry 266 10743-10749.
45. Faber PW, van Rooij HC, Schipper HJ, Brinkmann AO & Trapman J 1993 Two different, overlapping pathways of transcription initiation are active on the TATA-less human androgen receptor promoter. The role of Sp1. Journal of Biological Chemistry 268 9296-9301.
46. Furuyama T, Nakazawa T, Nakano I & Mori N 2000 Identification of the differential distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 homologues. Biochemical Journal 349 629-634. (doi:10.1042/0264-6021:3490629)
47. Gallia GL, Johnson EM & Khalili K 2000 Pura: a multifunctional singlestranded DNA- and RNA-binding protein. Nucleic Acids Research 28 3197-3205. (doi:10.1093/nar/28.17.3197)
48. Gasic GP 1994 Basic-helix-loop-helix transcription factor and sterol sensor in a single membrane-bound molecule. Cell 77 17-19. (doi:10.1016/0092-8674(94)90230-5)
49. Gilmore TD 1999 The Rel/NF-kB signal transduction pathway: introduction. Oncogene 18 6842-6844. (doi:10.1038/sj.onc.1203237)
50. Gilmore TD 2006 Introduction to NF-kB: players, pathways, perspectives. Oncogene 25 6680-6684. (doi:10.1038/sj.onc.1209954)
51. Goluboff ET, Shabsigh A, Saidi JA, Weinstein IB, Mitra N, Heitjan D, Piazza GA, Pamukcu R, Buttyan R & Olsson CA 1999 Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology 53 440-445. (doi:10.1016/S0090-4295(98)00513-5)
52. Goluboff ET, Prager D, Rukstalis D, Giantonio B, Madorsky M, Barken I, Weinstein IB, Partin AW, Olsson CA & UCLA Oncology Research Network 2001 Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. Journal of Urology 166 882-886. (doi:10.1016/S0022-5347(05)65856-9)
53. Gong Y, Blok LJ, Perry JE, Lindzey JK & Tindall DJ 1995 Calcium regulation of androgen receptor expression in the human prostate cancer cell line LNCaP. Endocrinology 136 2172-2178. (doi:10.1210/en.136.5.2172)
54. Grad JM, Dai JL, Wu S & Burnstein KL 1999 Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA. Molecular Endocrinology 13 1896-1911. (doi:10.1210/me.13.11.1896)
55. Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL & French FS 1998 Androgen receptor expression in androgenindependent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Research 58 5718-5724.
56. Gregory CW, Johnson RT Jr, Mohler JL, French FS & Wilson EM 2001 Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Research 61 2892-2898.
57. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG et al. 2009 A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Research 69 2305-2313. (doi:10.1158/0008-5472.CAN-08-3795)
58. Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, McLeod DG, Srivastava S & Petrovics G 2010 Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer and Prostatic Diseases 13 311-315. (doi:10.1038/pcan.2010.31)
59. He ML, Yuan HQ, Jiang AL, Gong AY, Chen WW, Zhang PJ, Young CY & Zhang JY 2006 Gum mastic inhibits the expression and function of the androgen receptor in prostate cancer cells. Cancer 106 2547-2555. (doi:10.1002/cncr.21935)
60. Heemers HV, Verhoeven G & Swinnen JV 2006 Androgen activation of the sterol regulatory element-binding protein pathway: current insights. Molecular Endocrinology 20 2265-2277. (doi:10.1210/me.2005-0479)
61. Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW & Srivastava S 1995 Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. Journal of Urology 154 414-421. (doi:10.1016/S0022-5347(01)67065-4)
62. Hermeking H 2003 The MYC oncogene as a cancer drug target. Current Cancer Drug Targets 3 163-175. (doi:10.2174/1568009033481949)
63. Hess J, Angel P & Schorpp-Kistner M 2004 AP-1 subunits: quarrel and harmony among siblings. Journal of Cell Science 117 5965-5973. (doi:10.1242/jcs.01589)
64. Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, Lin A, Kluger HM, Berger AJ, Cheng E, Trombetta ES et al. 2004 Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Research 64 5270-5282. (doi:10.1158/0008-5472.CAN-04-0731)
65. Hoshino K, Ishiguro H, Teranishi JI, Yoshida SI, Umemura S, Kubota Y & Uemura H 2010 Regulation of androgen receptor expression through angiotensin II type 1 receptor in prostate cancer cells. Prostate 71 964-975. (doi:10.1002/pros.21312)
66. Hsu JC, Zhang J, Dev A, Wing A, Bjeldanes LF & Firestone GL 2005 Indole-3-carbinol inhibition of androgen receptor expression and downregulation of androgen responsiveness in human prostate cancer cells. Carcinogenesis 26 1896-1904. (doi:10.1093/carcin/bgi155)
67. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB et al. 2009 Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Research 69 16-22. (doi:10.1158/0008-5472.CAN-08-2764)
68. Huang WC, Havel JJ, Zhau HE, Qian WP, Lue HW, Chu CY, Nomura T & Chung LW 2008 b2-Microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cells. Clinical Cancer Research 14 5341-5347. (doi:10.1158/1078-0432.CCR-08-0793)
69. Huang PH, Wang D, Chuang HC, Wei S, Kulp SK & Chen CS 2009 a-Tocopheryl succinate and derivatives mediate the transcriptional repression of androgen receptor in prostate cancer cells by targeting the PP2A-JNK-Sp1-signaling axis. Carcinogenesis 30 1125-1131. (doi:10.1093/carcin/bgp112)
70. Huang WC, Zhau HE & Chung LW 2010 Androgen receptor survival signaling is blocked by anti-b2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells. Journal of Biological Chemistry 285 7947-7956. (doi:10.1074/jbc.M109.092759)
71. Husbeck B, Bhattacharyya RS, Feldman D & Knox SJ 2006 Inhibition of androgen receptor signaling by selenite andmethylseleninic acid in prostate cancer cells: two distinct mechanisms of action. Molecular Cancer Therapeutics 5 2078-2085. (doi:10.1158/1535-7163.MCT-06-0056)
72. Hwang JJ, Kim YS, Kim MJ, Kim DE, Jeong IG & Kim CS 2010 Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells. Journal of Urology 184 2557-2564. (doi:10.1016/j.juro.2010.07.035)
73. Inoue T, Leman ES, Yeater DB & Getzenberg RH 2008 The potential role of purine-rich element binding protein (PUR) a as a novel treatment target for hormone-refractory prostate cancer. Prostate 68 1048-1056. (doi:10.1002/pros.20764)
74. Ismail HA, Lessard L, Mes-Masson AM & Saad F 2004 Expression of NfkB in prostate cancer lymph node metastases. Prostate 58 308-313. (doi:10.1002/pros.10335)
75. Isobe M, Emanuel BS, Givol D, Oren M & Croce CM 1986 Localization of gene for human p53 tumour antigen to band 17p13. Nature 320 84-85. (doi:10.1038/320084a0)
76. Itoh H, Wortman MJ, Kanovsky M, Uson RR, Gordon RE, Alfano N & Johnson EM 1998 Alterations in Pura levels and intracellular localization in the CV-1 cell cycle. Cell Growth and Differentiation 9 651-665.
77. Ittmann MM & Wieczorek R 1996 Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. Human Pathology 27 28-34. (doi:10.1016/S0046-8177(96)90134-3)
78. Iwata T, Schultz D, Hicks J, Hubbard GK, Mutton LN, Lotan TL, Bethel C, Lotz MT, Yegnasubramanian S, Nelson WG et al. 2010 MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS ONE 5 e9427. (doi:10.1371/journal.pone.0009427)
79. Jackson KM, Frazier MC & Harris WB 2007 Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer. Anticancer Research 27 1483-1488.
80. Johnson EM, Chen PL, Krachmarov CP, Barr SM, Kanovsky M, Ma ZW & Lee WH 1995 Association of human Pura with the retinoblastoma protein, Rb, regulates binding to the single-stranded DNA Pura recognition element. Journal of Biological Chemistry 270 24352-24360. (doi:10.1074/jbc.270.41.24352)
81. Kaltz-Wittmer C, Klenk U, Glaessgen A, Aust DE, Diebold J, Löhrs U & Baretton GB 2000 FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy. Laboratory Investigation 80 1455-1464.
82. Kang HY, Huang HY, Hsieh CY, Li CF, Shyr CR, Tsai MY, Chang C, Chuang YC & Huang KE 2009 Activin A enhances prostate cancer cell migration through activation of androgen receptor and is overexpressed in metastatic prostate cancer. Journal of Bone and Mineral Research 24 1180-1193. (doi:10.1359/jbmr.090219)
83. Kaseb AO, Chinnakannu K, Chen D, Sivanandam A, Tejwani S, Menon M, Dou QP & Reddy GP 2007 Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Research 67 7782-7788. (doi:10.1158/0008-5472.CAN-07-1483)
84. Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C & Vogelstein B 1991 Identification of p53 as a sequence-specific DNA-binding protein. Science 252 1708-1711. (doi:10.1126/science.2047879)
85. Kim J, Park H, Im JY, Choi WS & Kim HS 2007 Sodium butyrate regulates androgen receptor expression and cell cycle arrest in human prostate cancer cells. Anticancer Research 27 3285-3292.
86. Kuefer R, Hofer MD, Altug V, Zorn C, Genze F, Kunzi-Rapp K, Hautmann RE & Gschwend JE 2004 Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. British Journal of Cancer 90 535-541. (doi:10.1038/sj.bjc.6601510)
87. Kulp SK, Chen CS, Wang DS, Chen CY & Chen CS 2006 Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clinical Cancer Research 12 5199-5206. (doi:10.1158/1078-0432.CCR-06-0429)
88. Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X, Chua CW, Chan KW, Chan FL, Glackin C et al. 2005 Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Research 65 5153-5162. (doi:10.1158/0008-5472.CAN-04-3785)
89. Lee HH, Ho CT & Lin JK 2004 Theaflavin-3,30-digallate and penta-Ogalloyl- b-D-glucose inhibit rat liver microsomal 5a-reductase activity and the expression of androgen receptor in LNCaP prostate cancer cells. Carcinogenesis 25 1109-1118. (doi:10.1093/carcin/bgh106)
90. Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y & Gao AC 2006 Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate 66 1070-1075. (doi:10.1002/pros.20329)
91. Lee JG, Zheng R, McCafferty-Cepero JM, Burnstein KL, Nanus DM & Shen R 2009 Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells. Molecular Carcinogenesis 48 141-149. (doi:10.1002/mc.20462)
92. Lessard L, Mes-Masson AM, Lamarre L, Wall L, Lattouf JB & Saad F 2003 NF-kB nuclear localization and its prognostic significance in prostate cancer. BJU International 91 417-420. (doi:10.1046/j.1464-410X.2003.04104.x)
93. Lezon-Geyda K, Najfeld V & Johnson EM 2001 Deletions of PURA, at 5q31, and PURB, at 7p13, in myelodysplastic syndrome and progression to acute myelogenous leukemia. Leukemia 15 954-962. (doi:10.1038/sj.leu.2402108)
94. Li R, Wheeler T, Dai H, Frolov A, Thompson T & Ayala G 2004 High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. American Journal of Surgical Pathology 28 928-934. (doi:10.1097/00000478-200407000-00013)
95. Li Y, Wang L, Zhang M, Melamed J, Liu X, Reiter R, Wei J, Peng Y, Zou X, Pellicer A et al. 2009 LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Research 69 3332-3338. (doi:10.1158/0008-5472.CAN-08-3380)
96. Lim JT, Piazza GA, Pamukcu R, Thompson WJ & Weinstein IB 2003 Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells. Clinical Cancer Research 9 4972-4982.
97. Linja MJ, Savinainen KJ, Saramäki OR, Tammela TL, Vessella RL & Visakorpi T 2001 Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Research 61 3550-3555.
98. Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM Jr, Kristal AR, Santella RM, Probstfield JL, Moinpour CM, Albanes D et al. 2005 Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute 97 94-102. (doi:10.1093/jnci/dji009)
99. Litvinov IV, De Marzo AM & Isaacs JT 2003 Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? Journal of Clinical Endocrinology and Metabolism 88 2972-2982. (doi:10.1210/jc.2002-022038)
100. Liu S & Yamauchi H 2010 Etoposide induces growth arrest and disrupts androgen receptor signaling in prostate cancer cells. Oncology Reports 23 165-170. (doi:10.3892/or_00000730)
101. Loiarro M, Campo S, Arseni B, Rossi S, D'Alessio V, De Santis R, Sette C & Ruggiero V 2011 Anti-proliferative effect of a triazole derivative (ST1959) on LNCaP human prostate cancer cells through downregulation of cyclin and androgen receptor expression. Prostate 71 32-41. (doi:10.1002/pros.21219)
102. Lu W, Tinsley HN, Keeton A, Qu Z, Piazza GA & Li Y 2009 Suppression of Wnt/b-catenin signaling inhibits prostate cancer cell proliferation. European Journal of Pharmacology 602 8-14. (doi:10.1016/j.ejphar.2008.10.053)
103. Lynch RL, Konicek BW, McNulty AM, Hanna KR, Lewis JE, Neubauer BL & Graff JR 2005 The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation. Molecular Cancer Research 3 163-169. (doi:10.1158/1541-7786.MCR-04-0163)
104. Maddison LA, Sutherland BW, Barrios RJ & Greenberg NM 2004 Conditional deletion of Rb causes early stage prostate cancer. Cancer Research 64 6018-6025. (doi:10.1158/0008-5472.CAN-03-2509)
105. Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, Doglioni C, Beach DH & Hannon GJ 1999 Twist is a potential oncogene that inhibits apoptosis. Genes and Development 13 2207-2217. (doi:10.1101/gad.13.17.2207)
106. Marrocco DL, Tilley WD, Bianco-Miotto T, Evdokiou A, Scher HI, Rifkind RA, Marks PA, Richon VM & Butler LM 2007 Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Molecular Cancer Therapeutics 6 51-60. (doi:10.1158/1535-7163.MCT-06-0144)
107. Mashima T, Okabe S & Seimiya H 2010 Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth. Molecular Pharmacology 78 846-854. (doi:10.1124/mol.110.064790)
108. Matlashewski G, Lamb P, Pim D, Peacock J, Crawford L & Benchimol S 1984 Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. EMBO Journal 3 3257-3262.
109. McBride OW, Merry D & Givol D 1986 The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). PNAS 83 130-134. (doi:10.1073/pnas.83.1.130)
110. Mitchell SH, Zhu W & Young CY 1999 Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Research 59 5892-5895.
111. Miyamoto H, Messing EM & Chang C 2004 Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 61 332-353. (doi:10.1002/pros.20115)
112. Mizokami A, Yeh SY & Chang C 1994 Identification of 30,50-cyclic adenosine monophosphate response element and other cis-acting elements in the human androgen receptor gene promoter. Molecular Endocrinology 8 77-88. (doi:10.1210/me.8.1.77)
113. Molife LR, Attard G, Fong PC, Karavasilis V, Reid AH, Patterson S, Riggs CE Jr, Higano C, Stadler WM, McCulloch W et al. 2010 Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Annals of Oncology 21 109-113. (doi:10.1093/annonc/mdp270)
114. Myatt SS & Lam EW 2007 The emerging roles of forkhead box (Fox) proteins in cancer. Nature Reviews. Cancer 7 847-859. (doi:10.1038/nrc2223)
115. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nicholas WW, von Eschenbach AC & Conti CJ 1993 p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. Journal of the National Cancer Institute 85 1657-1669. (doi:10.1093/jnci/85.20.1657)
116. Nesslinger NJ, Shi XB & deVere White RW 2003 Androgenindependent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. Cancer Research 63 2228-2233.
117. Ngan S, Stronach EA, Photiou A, Waxman J, Ali S & Buluwela L 2009 Microarray coupled to quantitative RT-PCR analysis of androgenregulated genes in human LNCaP prostate cancer cells. Oncogene 28 2051-2063. (doi:10.1038/onc.2009.68)
118. Nicole DF, Karam E, Yuan-Wan S, John TP & Raghu S 2010 1,4-Phenylenebis(methylene)selenocyanate, but not selenomethionine, inhibits androgen receptor and Akt signaling in human prostate cancer cells. Cancer Prevention Research 3 975-984. (doi:10.1158/1940-6207.CAPR-10-0054)
119. Olson EN & Klein WH 1994 bHLH factors in muscle development: dead lines and commitments, what to leave in and what to leave out. Genes and Development 8 1-8. (doi:10.1101/gad.8.1.1)
120. Pan Y, Zhang JS, Gazi MH & Young CY 2003 The cyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun in prostate cancer cells. Cancer Epidemiology, Biomarkers and Prevention 12 769-774.
121. Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, Seeram N, Liker H, Wang H, Elashoff R et al. 2006 Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clinical Cancer Research 12 4018-4026. (doi:10.1158/1078-0432.CCR-05-2290)
122. Pardee AB, Li CJ & Reddy GP 2004 Regulation in S phase by E2F. Cell Cycle 3 1091-1094. (doi:10.4161/cc.3.9.1143)
123. Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, Cordon-Cardo C, Thaler HT & Dannenberg AJ 2005 Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2- independent mechanism. Clinical Cancer Research 11 1999-2007. (doi:10.1158/1078-0432.CCR-04-1877)
124. Pearson HB, Phesse TJ & Clarke AR 2009 K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse. Cancer Research 69 94-101. (doi:10.1158/0008-5472.CAN-08-2895)
125. Perkins ND 2007 Integrating cell-signalling pathways with NF-kB and IKK function. Nature Reviews. Molecular Cell Biology 8 49-62. (doi:10.1038/nrm2083)
126. Pruthi RS, Derksen JE & Moore D 2004 A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU International 93 275-278. (doi:10.1111/j.1464-410X.2004.04601.x)
127. Pruthi RS, Derksen JE, Moore D, Carson CC, Grigson G, Watkins C & Wallen E 2006 Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clinical Cancer Research 12 2172-2177. (doi:10.1158/1078-0432.CCR-05-2067)
128. Rathkopf D, Wong BY, Ross RW, Anand A, Tanaka E, Woo MM, Hu J, Dzik-Jurasz A, Yang W & Scher HI 2010 A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology 66 181-189. (doi:10.1007/s00280-010-1289-x)
129. Ravenna L, Gulino A, Lubrano C, Sciarra F, Di Silverio F, D'Eramo G, Vacca A, Felli MP, Maroder M, Frati L et al. 1995 Androgenic and antiandrogenic control on epidermal growth factor, epidermal growth factor receptor, and androgen receptor expression in human prostate cancer cell line LNCaP. Prostate 26 290-298. (doi:10.1002/pros.2990260604)
130. Ren F, Zhang S, Mitchell SH, Butler R & Young CY 2000 Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene 19 1924-1932. (doi:10.1038/sj.onc.1203511)
131. Rephaeli A, Blank-Porat D, Tarasenko N, Entin-Meer M, Levovich I, Cutts SM, Phillips DR, Malik Z & Nudelman A 2005 In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer. International Journal of Cancer 116 226-235. (doi:10.1002/ijc.21030)
132. Rokhlin OW, Glover RB, Guseva NV, Taghiyev AF, Kohlgraf KG & Cohen MB 2006 Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells. Molecular Cancer Research 4 113-123. (doi:10.1158/1541-7786.MCR-05-0085)
133. Roose J & Clevers H 1999 TCF transcription factors: molecular switches in carcinogenesis. Biochimica et Biophysica Acta 1424 M23-M37. (doi:10.1016/S0304-419X(99)00026-8)
134. Rosivatz E, Becker I, Specht K, Fricke E, Luber B, Busch R, Höfler H & Becker KF 2002 Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. American Journal of Pathology 161 1881-1891. (doi:10.1016/S0002-9440(10)64464-1)
135. Rosner IL, Ravindranath L, Furusato B, Chen Y, Gao C, Cullen J, Sesterhenn IA, McLeod DG, Srivastava S & Petrovics G 2007 Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy. Urology 70 1225-1229. (doi:10.1016/j.urology.2007.09.010)
136. Roy-Burman P, Tindall DJ, Robins DM, Greenberg NM, Hendrix MJ, Mohla S, Getzenberg RH, Isaacs JT & Pienta KJ 2005 Androgens and prostate cancer: are the descriptors valid? Cancer Biology and Therapy 4 4-5.
137. Sargeant AM, Rengel RC, Kulp SK, Klein RD, Clinton SK, Wang YC & Chen CS 2008 OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Research 68 3999-4009. (doi:10.1158/0008-5472.CAN-08-0203)
138. Scher HI & Sawyers CL 2005 Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. Journal of Clinical Oncology 23 8253-8261. (doi:10.1200/JCO.2005.03.4777)
139. Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, Gallagher R, O'Sullivan JM, Johnston PG & Waugh DJ 2008 Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis 29 1148-1156. (doi:10.1093/carcin/bgn109)
140. Seo YK, Zhu B, Jeon TI & Osborne TF 2009 Regulation of steroid 5-a reductase type 2 (Srd5a2) by sterol regulatory element binding proteins and statin. Experimental Cell Research 315 3133-3139. (doi:10.1016/j.yexcr.2009.05.025)
141. Shabbeer S, Kortenhorst MS, Kachhap S, Galloway N, Rodriguez R & Carducci MA 2007 Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate 67 1099-1110. (doi:10.1002/pros.20587)
142. Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C, Morrissey C, Zhang X, Comstock CE, Witkiewicz AK et al. 2010 The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. Journal of Clinical Investigation 120 4478-4492. (doi:10.1172/JCI44239)
143. Shigemura K, Shirakawa T, Wada Y, Kamidono S, Fujisawa M & Gotoh A 2005 Antitumor effects of etodolac, a selective cyclooxygenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivo. Urology 66 1239-1244. (doi:10.1016/j.urology.2005.06.076)
144. Shiota M, Yokomizo A, Tada Y, Inokuchi J, Kashiwagi E, Masubuchi D, Eto M, Uchiumi T & Naito S 2010 Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression. Oncogene 29 237-250. (doi:10.1038/onc.2009.322)
145. Siu YT & Jin DY 2007 CREB - a real culprit in oncogenesis. FEBS Journal 274 3224-3232. (doi:10.1111/j.1742-4658.2007.05884.x)
146. Skurk C, Maatz H, Kim HS, Yang J, Abid MR, Aird WC & Walsh K 2004 The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. Journal of Biological Chemistry 279 1513-1525. (doi:10.1074/jbc.M304736200)
147. Sobel RE & Sadar MD 2005 Cell lines used in prostate cancer research: a compendium of old and new lines - part 1. Journal of Urology 173 342-359. (doi:10.1097/01.ju.0000141580.30910.57)
148. Stacey DW, Hitomi M, Kanovsky M, Gan L & Johnson EM 1999 Cell cycle arrest and morphological alterations following microinjection of NIH3T3 cells with Pura. Oncogene 18 4254-4261. (doi:10.1038/sj.onc.1202795)
149. Su-Hyeong K & Shivendra VS 2009 D,L-sulforaphane causes transcriptional repression of androgen receptor in human prostate cancer cells. Molecular Cancer Therapeutics 8 1946-1954. (doi:10.1158/1535-7163.MCT-09-0104)
150. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H et al. 2010 Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. Journal of Clinical Investigation 120 2715-2730. (doi:10.1172/JCI41824)
151. Supakar PC, Jung MH, Song CS, Chatterjee B & Roy AK 1995 Nuclear factor k B functions as a negative regulator for the rat androgen receptor gene and NF-kB activity increases during the agedependent desensitization of the liver. Journal of Biological Chemistry 270 837-842. (doi:10.1074/jbc.270.2.837)
152. Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldridge LA, Gardner T, Smith M, Nakshatri H & Cheng L 2004 Nuclear factor-kB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clinical Cancer Research 10 5501-5507. (doi:10.1158/1078-0432.CCR-0571-03)
153. Swinnen JV, Heemers H, van de Sande T, de Schrijver E, Brusselmans K, Heyns W & Verhoeven G 2004 Androgens, lipogenesis and prostate cancer. Journal of Steroid Biochemistry and Molecular Biology 92 273-279. (doi:10.1016/j.jsbmb.2004.10.013)
154. Takane KK & McPhaul MJ 1996 Functional analysis of the human androgen receptor promoter. Molecular and Cellular Endocrinology 119 83-93. (doi:10.1016/0303-7207(96)03800-2)
155. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ et al. 2003 Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. Journal of Clinical Oncology 21 2673-2678. (doi:10.1200/JCO.2003.11.102)
156. Tepper CG, Vinall RL, Wee CB, Xue L, Shi XB, Burich R, Mack PC & de Vere White RW 2007 GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms. Prostate 67 521-535. (doi:10.1002/pros.20548)
157. Tian B & Brasier AR 2003 Identification of a nuclear factor k B-dependent gene network. Recent Progress in Hormone Research 58 95-130. (doi:10.1210/rp.58.1.95)
158. Tilley WD, Marcelli M & McPhaul MJ 1990 Expression of the human androgen receptor gene utilizes a common promoter in diverse human tissues and cell lines. Journal of Biological Chemistry 265 13776-13781.
159. Tiniakos DG, Mitropoulos D, Kyroudi-Voulgari A, Soura K & Kittas C 2006 Expression of c-Jun oncogene in hyperplastic and carcinomatous human prostate. Urology 67 204-208. (doi:10.1016/j.urology.2005.07.045)
160. Titus MA, Schell MJ, Lih FB, Tomer KB & Mohler JL 2005 Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clinical Cancer Research 11 4653-4657. (doi:10.1158/1078-0432.CCR-05-0525)
161. Vander Griend DJ, Antony L, Dalrymple SL, Xu Y, Christensen SB, Denmeade SR & Isaacs JT 2009 Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells. Molecular Cancer Therapeutics 8 1340-1349. (doi:10.1158/1535-7163.MCT-08-1136)
162. Verras M & Sun Z 2006 Roles and regulation of Wnt signaling and b-catenin in prostate cancer. Cancer Letters 237 22-32. (doi:10.1016/j.canlet.2005.06.004)
163. Wang X, Sato R, Brown MS, Hua X & Goldstein JL 1994 SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. Cell 77 53-62. (doi:10.1016/0092-8674(94)90234-8)
164. Wang LG, Ossowski L & Ferrari AC 2004 Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line. Oncogene 23 5175-5184. (doi:10.1038/sj.onc.1207654)
165. Wang LG, Liu XM & Chiao JW 2006 Repression of androgen receptor in prostate cancer cells by phenethyl isothiocyanate. Carcinogenesis 27 2124-2132. (doi:10.1093/carcin/bgl075)
166. Wang LG, Johnson EM, Kinoshita Y, Babb JS, Buckley MT, Liebes LF, Melamed J, Liu XM, Kurek R, Ossowski L et al. 2008 Androgen receptor overexpression in prostate cancer linked to Pura loss from a novel repressor complex. Cancer Research 68 2678-2688. (doi:10.1158/0008-5472.CAN-07-6017)
167. Wu D, Zhau HE, Huang WC, Iqbal S, Habib FK, Sartor O, Cvitanovic L, Marshall FF, Xu Z & Chung LW 2007 cAMP-responsive elementbinding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. Oncogene 26 5070-5077. (doi:10.1038/sj.onc.1210316)
168. Xing N, Chen Y, Mitchell SH & Young CY 2001 Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis 22 409-414. (doi:10.1093/carcin/22.3.409)
169. Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B & Sun Z 2002 Linking b-catenin to androgen-signaling pathway. Journal of Biological Chemistry 277 11336-11344. (doi:10.1074/jbc.M111962200)
170. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A & Weinberg RA 2004 Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117 927-939. (doi:10.1016/j.cell.2004.06.006)
171. Yang L, Xie S, Jamaluddin MS, Altuwaijri S, Ni J, Kim E, Chen YT, Hu YC, Wang L, Chuang KH et al. 2005 Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. Journal of Biological Chemistry 280 33558-33565. (doi:10.1074/jbc.M504461200)
172. Yang X, Chen MW, Terry S, Vacherot F, Bemis DL, Capodice J, Kitajewski J, de la Taille A, Benson MC, Guo Y et al. 2006 Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells. Oncogene 25 3436-3444. (doi:10.1038/sj.onc.1209366)
173. Yardy GW & Brewster SF 2005 Wnt signalling and prostate cancer. Prostate Cancer and Prostatic Diseases 8 119-126. (doi:10.1038/sj.pcan. 4500794)
174. Yeh S, Miyamoto H, Nishimura K, Kang H, Ludlow J, Hsiao P, Wang C, Su C & Chang C 1998 Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells. Biochemical and Biophysical Research Communications 248 361-367. (doi:10.1006/bbrc.1998.8974)
175. Yokoyama C, Wang X, Briggs MR, Admon A, Wu J, Hua X, Goldstein JL & Brown MS 1993 SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell 75 187-197.
176. Yu X, Wang Y, Degraff DJ, Wills ML & Matusik RJ 2010 Wnt/b-catenin activation promotes prostate tumor progression in a mouse model. Oncogene 30 1868-1879. (doi:10.1038/onc.2010.560)
177. Yuan H, Pan Y & Young CY 2004 Overexpression of c-Jun induced by quercetin and resverol inhibits the expression and function of the androgen receptor in human prostate cancer cells. Cancer Letters 213 155-163. (doi:10.1016/j.canlet.2004.04.003)
178. Yuan H, Gong A & Young CY 2005 Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells. Carcinogenesis 26 793-801. (doi:10.1093/carcin/bgi021)
179. Yuan HQ, Kong F, Wang XL, Young CY, Hu XY & Lou HX 2008 Inhibitory effect of acetyl-11-keto-b-boswellic acid on androgen receptor by interference of Sp1 binding activity in prostate cancer cells. Biochemical Pharmacology 75 2112-2121. (doi:10.1016/j.bcp.2008.03.005)
180. Yuen HF, Chua CW, Chan YP, Wong YC, Wang X & Chan KW 2007 Significance of TWIST and E-cadherin expression in the metastatic progression of prostatic cancer. Histopathology 50 648-658. (doi:10.1111/j.1365-2559.2007.02665.x)
181. Zegarra-Moro OL, Schmidt LJ, Huang H & Tindall DJ 2002 Disruption of androgen function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Research 62 1008-1013.
182. Zhang L, Charron M, Wright WW, Chatterjee B, Song CS, Roy AK & Brown TR 2004 Nuclear factor-kB activates transcription of the androgen receptor gene in Sertoli cells isolated from testes of adult rats. Endocrinology 145 781-789. (doi:10.1210/en.2003-0987)
183. Zhang Y, Wang XW, Jelovac D, Nakanishi T, Yu MH, Akinmade D, Goloubeva O, Ross DD, Brodie A & Hamburger AW 2005 The ErbB3-binding protein Ebp1 suppresses androgen receptormediated gene transcription and tumorigenesis of prostate cancer cells. PNAS 102 9890-9895. (doi:10.1073/pnas.0503829102)
184. Zhang L, Altuwaijri S, Deng F, Chen L, Lal P, Bhanot UK, Korets R, Wenske S, Lilja HG, Chang C et al. 2009 NF-kB regulates androgen receptor expression and prostate cancer growth. American Journal of Pathology 175 489-499. (doi:10.2353/ajpath.2009.090275)
185. Zhao XY, Ly LH, Peehl DM & Feldman D 1999 Induction of androgen receptor by 1a,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 140 1205-1212. (doi:10.1210/en.140.3.1205)
186. Zhao H, Whitfield ML, Xu T, Botstein D & Brooks JD 2004 Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells. Molecular Biology of the Cell 15 506-519. (doi:10.1091/mbc.E03-07-0501)
187. Zhou Z, Flesken-Nikitin A, Corney DC, Wang W, Goodrich DW, Roy-Burman P & Nikitin AY 2006 Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Research 66 7889-7898. (doi:10.1158/0008-5472.CAN-06-0486)